AZD1208 (Synonyms: AZD 1208;AZD-1208) |
カタログ番号GC12660 |
パン-Pimキナーゼ阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1204144-28-4
Sample solution is provided at 25 µL, 10mM.
AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor, with IC50 values of 0.4, 5, and 1.9nM for PIM1, PIM2, and PIM3, respectively[1,2]. AZD1208 is a thiazolidine that is known for its anti-cancer activity[3]
AZD1208 has anti-adipogenic and lipolytic effects on 3T3-L1 adipocytes through control of the expression and/or phosphorylation levels of PPAR-c, C/EBP-a, FAS, ACC, perilipin A, STAT-3, AMPK and HSL, that advocate AZD1208 as a potential therapeutics for the treatment of obesity[3]. AZD1208 resulted in suppression of mTOR signaling, including inhibition of protein phosphorylation of mTOR(Ser2448), p70S6K(Thr389), S6(Ser235/236) and 4E-BP1(Ser65)[4]. Treatment with AZD1208 alone induced considerable cell death through autophagy in gastric cancer cells. AZD1208 combines with an Akt inhibitor (AZD5363) showed synergistic antitumor effects through regulation of the DNA damage repair pathway[5]
AZD1208 dose-dependent inhibits the growth of MOLM-16 xenograft tumors in vivo. Treatment with 10mg/kg or 30mg/kg of AZD1208 led to 89% tumor growth inhibition or slight regression, respectively[2]. AZD1208 decreased the growth of tumors comprised of hepatoblastoma CD133-enriched cells, with 57% of the animals experiencing complete tumor regression in a vivo xenograft model[6]. AZD1208 was generally tolerated in patients with heavily pretreated AML (120–900 mg dose range) and advanced solid malignancies (120–800 mg dose range). AZD1208 increased CYP3A4 activity after multiple dosing, resulting in increased drug clearance[6]
References:
[1]. Cervantes-Gomez F, Stellrecht CM, et al. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 2019;10(29):2793-2809. Published 2019 Apr 19.
[2]. Keeton EK, McEachern K, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123(6):905-913
[3]. Park YK, Obiang-Obounou BW, et al. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes. J Cell Mol Med. 2018;22(4):2488-2497.
[4]. Chen LS, Yang JY, et al. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016;57(12):2863-2873.
[5]. Lee M, Lee KH, et al. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. Cancer Res Treat. 2019;51(2):451-463.
[6]. Stafman LL, Williams AP, et al. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma. Transl Oncol. 2019;12(2):200-208.
[7]. Cortes J, Tamura K, et al. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018;118(11):1425-1433.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *